Jump to content
Main menu
Main menu
move to sidebar
hide
Navigation
Main page
Recent changes
Random page
Help about MediaWiki
Special pages
Surgopaedia
Search
Search
Appearance
Create account
Log in
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Editing
Non-melanoma skin cancer
(section)
Page
Discussion
English
Read
Edit
Edit source
View history
Tools
Tools
move to sidebar
hide
Actions
Read
Edit
Edit source
View history
General
What links here
Related changes
Page information
Appearance
move to sidebar
hide
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== '''SCC''' == === Risk factors === *** Exposure to sunlight - cumulative chronic UV radiation **** Direct carcinogenic effect of UV light on the keratinocytes within the basal layer of the epidermis *** Susceptible skin types *** Compromised immunity **** Especially after transplant - 65x that of normal population *** Environmental exposures **** Arsenic **** Organic hydrocarbons **** Ionising radiation **** Cigarette smoke *** Underlying genetic disorders **** Xeroderma pigmentosum **** Albinism === Pathophysiology === *** Arise as a proliferation of keratin cells in the basal layer of epidermis - appear as red or pink areas (actinic/solar keratoses). *** >90% have p53 silencing *** Classification: (divide into two main groups) **** Well-differentiated **** Moderately, poorly, and undifferentiated ***** Worse prognosis ***** Tend to treat with wider and deeper margins, consider SLNB if >2cm wide or 2mm deep, and histologic confirmation of margins prior to closure/reconstruction *** Subtypes **** Keratoacanthoma - subtype of invasive SCC **** Marjolin's ulcer - arises in chronic scarred tissue - burn scars, draining sinuses, infections ***** Refers to all skin cancers within damaged tissue, but is most commonly SCC ***** Malignant transformation due to chronic inflammation, repeated injury, and impaired immune surveillance within non-healing wounds or scars ***** Aggressive, poor prognosis, high recurrence rate, much higher metastatic potential than non-Marjolin SCC ***** Commonly excised with 2-3cm margins down to fascia. Amputate if there is bony involvement or WLE is impossible. Lymphadenectomy or radiotherapy to nodes. === Clinically === *** Most frequent on face, hands, forearms *** More indolent when it arises in chronically sun-exposed areas *** Hyperkeratotic, flesh-coloured, raised, with possible ulceration or erythema **** Pre-malignant: scaly lesions with an uneven surface and an erythematous base **** Invasive: palpable, scaling lesions with central ulcerations and elevated, firm edges === Risk profile === *** From Sabiston: ** *** Based on 2021 NCCN guidelines **** High-risk cutaneous SCC: ***** Lesions of any size on head/neck, feet, pretibia, anogenital regions ***** Lesions >=2cm on trunk or extremities ***** Recurrent tumour ***** Histopathologically acantholytic, adenosquamous (mucin production), or metaplastic (carcinosarcomatous) subtypes ***** Perineural invasion **** Very high-risk: ***** Lesions >=4cm in any location ***** Histopathologically poorly differentiated tumour ***** Desmoplastic cSCC ***** >6mm thickness ***** Invasion beyond subcutaneous fat ***** PNI - tumour cells within the nerve of a nerve lying deeper than the dermis or >=0.1mm ***** Lymphatic or vascular involvement === Work-up === **** Indications for imaging: (CT or MRI is best tool for finding nodes) ***** Tumour >2cm ***** Tumours near major head/neck nerves ***** In transit mets ***** Tumours invading deep structures ***** Systemic signs or symptoms of extracutaneous involvement ***** Findings suggestive of perineural invasion ***** Multiple high-risk features === Staging === **** There isn't an AJCC staging TNM system for non-head and neck SCC '''Brigham and Women's Hospital tumor (T) staging system for cutaneous squamous cell carcinoma''' {| class="wikitable" |'''Tumor staging system''' |'''Definition''' |- |'''BWH''' | |- |T1 |0 high-risk factors* |- |T2a |1 high-risk factor |- |T2b |2 to 3 high-risk factors |- |T3 |β₯4 high-risk factors or bone invasion |} ** Use very high-risk features above, only difference size cut-off for this can be >-2cm instead of >=4cm === '''Treatment''' === *** '''Local options:''' **** Excision with 5-10mm margins (depending on ease of reaching these margins, and risk profile of lesion) ***** Often surrounding inflammation and hard to determine the exact extent of tumour. Can perform punch biopsies prior to excision. May just need to treat the edge of inflammation as the edge of the lesion. ***** MMS can be a good option for sensitive areas **** Field therapies ***** Cryotherapy (small superficial lesions - effective >90%) ***** Curettage - superficial lesions <2cm ***** Topical therapies ****** See separate section under 'oncology' ****** Biopsy is indicated when the actinic keratosis is raised or recurrent after topical therapy ***** Electrodessication and curettage ***** Carbon dioxide laser ***** Dermabrasion ***** Chemical peel *** '''Management of nodal disease:''' **** Aggressive surgical resection of involved nodal disease **** One positive lymph node <3cm with no extracapsular extension can also have adjuvant RTX **** SLNB indications are not well-defined, but can be considered for high-risk lesions ** Adjuvant radiotherapy indications: *** High-risk tumours with clear margins *** Salvage therapy for incomplete resection *** Perineural invasion *** Recurrence following clear margins ** Adjuvant systemic therapy *** Usually platinum-based with variable response rates *** There is a new PD-1 inhibitor (cemiplimab), however advanced SCC remains a difficult disease to treat ** Follow-up: full skin examination and regional node examination *** Local disease: every 3-6 months for 2 years, then 6-12 months for 3 years, then annually for life *** Regional: 1-3 months for 1 year, then 2-4 months for 1 year, the 4-6 months for 3 years, then 6-12 months for life
Summary:
Please note that all contributions to Surgopaedia may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Surgopaedia:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Search
Search
Editing
Non-melanoma skin cancer
(section)
Add topic